Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

All patients will have similar induction and consolidation treatment with the same regimen.

DRUG

Lenalidomide

All patients will have similar induction and consolidation treatment with the same regimen.

DRUG

Dexamethasone

All patients will have similar induction and consolidation treatment with the same regimen.

Trial Locations (26)

Unknown

Helsinki University Central Hospital, Helsinki

Central Finland Central Hospital, Jyväskylä

Kainuu Central Hospital, Kajaani

Kymenlaakso Central Hospital, Kotka

Kuopio University Hospital, Kuopio

Päijät-Häme Central Hospital, Lahti

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

VIlnius University Hospital, Vilnius

Forde Central Hospital South, Førde

Oslo University Hospital, Oslo

Stavanger University Hospital, Stavanger

Trondheim University Hospital, Trondheim

Borås University Hospital, Borås

Göteborg University Hospital, Gothenburg

Halmstad Hospital Region Halland, Halmstad

Linköping University Hospital, Linköping

Sunderby Hospital Region Norrbotten, Luleå

Lund University Hospital, Lund

Örebro University Hospital, Örebro

Helsingborg Hospital Skane, Skåne

Karolinska University Hospital, Stockholm

Uddevalla Hospital, Uddevalla

Uppsala University Hospital, Uppsala

Varberg Hospital, Varberg

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Nordic Myeloma Study Group

OTHER

collaborator

Celgene

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

Raija Silvennoinen

OTHER

NCT03376672 - Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | Biotech Hunter | Biotech Hunter